Diabetes, Vol 48, Issue 5 1108-1112, Copyright © 1999 by American Diabetes Association

ARTICLES

Tumor necrosis factor system activity is associated with insulin resistance and dyslipidemia in myotonic dystrophy

JM Fernandez-Real, A Molina, M Broch, W Ricart, C Gutierrez, R Casamitjana, J Vendrell, J Soler and JM Gomez-Saez
Unitat de Diabetes, Endocrinologia, i Nutricio, University Hospital of Girona Dr. Josep Trueta, Spain. hosptrueta@comg.es

Myotonic dystrophy (MyD) is a multisystem autosomal dominant disorder associated with progressive muscle wasting and weakness. The striking metabolic abnormality in MyD is insulin resistance. The mechanism by which target tissues are insensitive to insulin action remains uncertain. In a recent study, plasma soluble tumor necrosis factor receptor (sTNFR)2 levels were found to be associated with muscle tissue mass and insulin resistance. Given these associations, we speculated that disorders of the muscle cell membrane could lead simultaneously to insulin insensitivity and sTNFR2 leakage in MyD. To test this hypothesis, we measured the levels of circulating sTNFR1 and sTNFR2 and insulin resistance in MyD patients. We studied 22 MyD patients and 24 age-, BMI-, and fat mass-matched control subjects. Both MyD men and women showed higher plasma insulin levels in the presence of comparable glucose concentrations than did control subjects. sTNFR2, but not sTNFR1, levels were approximately 1.5-fold higher in MyD patients. In parallel with these findings, the fasting insulin resistance index (FIRI) was also higher in MyD patients. In fact, in the whole population, fasting insulin and FIRI strongly correlated with sTNFR2 in both men (r = 0.77 and r = 0.81, P<0.0001, respectively) and women (r = 0.67 and r = 0.64, P = 0.001, respectively). sTNFR2 levels were also associated with the insulin sensitivity index (S(I)), calculated from an oral glucose tolerance test (OGTT) according to the method by Cederholm and Wibell (r = -0.43, P = 0.006). We constructed a multiple linear regression to predict FIRI, with BMI, waist-to-hip ratio, and sTNFR2 as independent variables. In this model, both BMI (P = 0.0014) and sTNFR2 (P = 0.0048) levels contributed independently to 46% of the variance of FIRI. In another model, in which FIRI was substituted for S(I) from the OGTT, both BMI (P = 0.0001) and sTNFR2 (P = 0.04) levels contributed independently to 48% of the variance of S(I) from the OGTT. Plasma cholesterol and triglyceride concentrations were significantly increased in MyD patients. sTNFR1 and sTNFR2 levels were found to be strongly associated with plasma cholesterol, LDL cholesterol, and triglycerides. sTNFR1 and sTNFR2 also correlated with serum creatine kinase activity in MyD patients (r = 0.57, P = 0.006; r = 0.75, P<0.0001, respectively). In conclusion, here we describe, for the first time to our knowledge, a relationship between insulin action and plasma sTNFR2 concentration in MyD patients. We have also found increased concentrations of plasma triglycerides and cholesterol levels in parallel with sTNFR1 and sTNFR2 concentrations in MyD patients. We speculate that the latter associations are dependent on, and secondary to, increased tumor necrosis factor (TNF)-alpha action. Whether TNF action is implicated in the pathogenesis of MyD or is a simple marker of disease activity awaits further studies.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. Gagnon, L. Noreau, R. T Moxley, L. Laberge, S. Jean, L. Richer, M. Perron, S. Veillette, and J. Mathieu Towards an integrative approach to the management of myotonic dystrophy type 1 J. Neurol. Neurosurg. Psychiatry, August 1, 2007; 78(8): 800 - 806. [Full Text] [PDF]

				J. M. Fernandez-Real, M. Straczkowski, B. Lainez, M. R Chacon, I. Kowalska, A. Lopez-Bermejo, A. Garcia-Espana, A. Nikolajuk, I. Kinalska, and W. Ricart An alternative spliced variant of circulating soluble tumor necrosis factor-{alpha} receptor-2 is paradoxically associated with insulin action. Eur. J. Endocrinol., May 1, 2006; 154(5): 723 - 730. [Abstract] [Full Text] [PDF]

				J.-M. Fernandez-Real, J. Vendrell, and W. Ricart Circulating Adiponectin and Plasma Fatty Acid Profile Clin. Chem., March 1, 2005; 51(3): 603 - 609. [Abstract] [Full Text] [PDF]

				M. Recasens, A. Lopez-Bermejo, W. Ricart, J. Vendrell, R. Casamitjana, and J. M. Fernandez-Real An Inflammation Score Is Better Associated with Basal than Stimulated Surrogate Indexes of Insulin Resistance J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 112 - 116. [Abstract] [Full Text] [PDF]

				G. Perseghin, M. Comola, P. Scifo, S. Benedini, F. De Cobelli, R. Lanzi, F. Costantino, G. Lattuada, A. Battezzati, A. Del Maschio, et al. Postabsorptive and insulin-stimulated energy and protein metabolism in patients with myotonic dystrophy type 1 Am. J. Clinical Nutrition, August 1, 2004; 80(2): 357 - 364. [Abstract] [Full Text] [PDF]

				J. M. Fernandez-Real, A. Lopez-Bermejo, M. Broch, J. Vendrell, C. Richart, and W. Ricart Circulating Soluble CD14 Monocyte Receptor Is Associated with Increased Alanine Aminotransferase Clin. Chem., August 1, 2004; 50(8): 1456 - 1458. [Full Text] [PDF]

				M. Straczkowski, I. Kowalska, A. Nikolajuk, S. Dzienis-Straczkowska, I. Kinalska, M. Baranowski, M. Zendzian-Piotrowska, Z. Brzezinska, and J. Gorski Relationship Between Insulin Sensitivity and Sphingomyelin Signaling Pathway in Human Skeletal Muscle Diabetes, May 1, 2004; 53(5): 1215 - 1221. [Abstract] [Full Text] [PDF]

				J. A. Johnson, J. B. Albu, E. S. Engelson, S. K. Fried, Y. Inada, G. Ionescu, and D. P. Kotler Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy Am J Physiol Endocrinol Metab, February 1, 2004; 286(2): E261 - E271. [Abstract] [Full Text] [PDF]

				J. M. Fernandez-Real and W. Ricart Insulin Resistance and Chronic Cardiovascular Inflammatory Syndrome Endocr. Rev., June 1, 2003; 24(3): 278 - 301. [Abstract] [Full Text] [PDF]

				J.-M. Fernandez-Real, M. Broch, J. Vendrell, and W. Ricart Insulin Resistance, Inflammation, and Serum Fatty Acid Composition Diabetes Care, May 1, 2003; 26(5): 1362 - 1368. [Abstract] [Full Text] [PDF]

				J. M. Fernandez-Real, M. Broch, C. Richart, J. Vendrell, A. Lopez-Bermejo, and W. Ricart CD14 Monocyte Receptor, Involved in the Inflammatory Cascade, and Insulin Sensitivity J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1780 - 1784. [Abstract] [Full Text] [PDF]

				S. Dzienis-Straczkowska, M. Straczkowski, M. Szelachowska, A. Stepien, I. Kowalska, and I. Kinalska Soluble Tumor Necrosis Factor-{alpha} Receptors in Young Obese Subjects With Normal and Impaired Glucose Tolerance Diabetes Care, March 1, 2003; 26(3): 875 - 880. [Abstract] [Full Text] [PDF]

				J.-M. Fernandez-Real, M. Pugeat, M. Grasa, M. Broch, J. Vendrell, J. Brun, and W. Ricart Serum Corticosteroid-Binding Globulin Concentration and Insulin Resistance Syndrome: A Population Study J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4686 - 4690. [Abstract] [Full Text] [PDF]

				M. Straczkowski, I. Kowalska, A. Stepien, S. Dzienis-Straczkowska, M. Szelachowska, and I. Kinalska Increased Plasma-Soluble Tumor Necrosis Factor-{alpha} Receptor 2 Level in Lean Nondiabetic Offspring of Type 2 Diabetic Subjects Diabetes Care, October 1, 2002; 25(10): 1824 - 1828. [Abstract] [Full Text] [PDF]

				B. Peral, J. L. San Millan, R. Castello, P. Moghetti, and H. F. Escobar-Morreale The Methionine 196 Arginine Polymorphism in Exon 6 of the TNF Receptor 2 Gene (TNFRSF1B) Is Associated with the Polycystic Ovary Syndrome and Hyperandrogenism J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3977 - 3983. [Abstract] [Full Text] [PDF]

				A. Johansson, R. Andrew, H. Forsberg, K. Cederquist, B. R. Walker, and T. Olsson Glucocorticoid Metabolism and Adrenocortical Reactivity to ACTH in Myotonic Dystrophy J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4276 - 4283. [Abstract] [Full Text] [PDF]

				A. V. Benjafield, C. L. Glenn, X. L. Wang, S. Colagiuri, and B. J. Morris TNFRSF1B in Genetic Predisposition to Clinical Neuropathy and Effect on HDL Cholesterol and Glycosylated Hemoglobin in Type 2 Diabetes Diabetes Care, April 1, 2001; 24(4): 753 - 757. [Abstract] [Full Text]

				A. Johansson, K. Carlström, B. Ahrén, K. Cederquist, E. Krylborg, H. Forsberg, and T. Olsson Abnormal Cytokine and Adrenocortical Hormone Regulation in Myotonic Dystrophy J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3169 - 3176. [Abstract] [Full Text]

				C. L. Glenn, W. Y.S. Wang, A. V. Benjafield, and B. J. Morris Linkage and association of tumor necrosis factor receptor 2 locus with hypertension, hypercholesterolemia and plasma shed receptor Hum. Mol. Genet., August 12, 2000; 9(13): 1943 - 1949. [Abstract] [Full Text] [PDF]

				E. Ledru, N. Christeff, O. Patey, P. de Truchis, J.-C. Melchior, and M.-L. Gougeon Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome Blood, May 15, 2000; 95(10): 3191 - 3198. [Abstract] [Full Text] [PDF]